Data Editor, Pharma
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Hodgson
The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.
Keith Blundy, CEO of STORM Therapeutics, discusses the company’s founding and upcoming milestones.
Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how this financing arm aligns with Novo’s broader strategy.
IOnctura’s CEO Catherine Pickering outlines the company’s business model and its approach to cancer R&D targeting the tumor microenvironment.
Merger and acquisition, or collaboration at least, was in the air during March as big pharma took stock of its opportunities in the midst of a disturbed market.
Demand for the top-selling drug, Humira, continues to break all sales records, leading a charge in which, for the first time, a majority of the top 30 selling drugs were biologics. But 2017 also saw one multiple blockbuster drug lose over 75% of it's sales for reasons other than loss of exclusivity or market withdrawal.